Overall Survival as Primary End Point in advanced soft tissue sarcoma and it's surrogates - a bemusing mirage

Sarcoma Research International

Rastogi S, Mishra SV and Aggarwal A. Overall Survival as Primary End Point in Advanced Soft Tissue

Advanced soft tissue sarcoma is extremely complex and heterogenous disease with dismal outcomes. The advent of newer drugs like pazopanib, trabectedin and most recently eribulin has enabled a flexible and more individualized approach to the treatment of advanced soft tissue sarcoma. However, given their modest benefit, it becomes essential to evaluate if we are using appropriate end points in the current trials and how the equation between progression free survival and overall survival might change in future.
July 2016
38 Reads

Similar Publications